+关注
Henrywong
暂无个人介绍
IP属地:未知
2
关注
0
粉丝
0
主题
0
勋章
主贴
热门
Henrywong
2022-01-22
It is completely wrong logic for stock options to drive stock price. Over trading in stock options has now become a problem
A $3.3 Trillion Expiry of Stock Options Adds to Market Jitters
Henrywong
2022-01-15
People are dreaming and think that electric car are flying out of the showrooms. Elon Musk certainly has successfully build your dream more than BYD
Are Electric Vehicle Stocks Overhyped?
Henrywong
2022-01-14
Start flying high
抱歉,原内容已删除
Henrywong
2021-12-23
Good
Tesla, authorities submit documents for German plant approval
Henrywong
2021-12-23
👍
Netflix Rally in 2022 Hinges on Finding the Next ‘Squid Game’
Henrywong
2021-12-23
👍
Tesla’s Touch-Screen Gaming Probed by U.S. Auto-Safety Regulator
Henrywong
2021-12-23
👍
U.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3584951930259825,"uuid":"3584951930259825","gmtCreate":1621859785241,"gmtModify":1639480231403,"name":"Henrywong","pinyin":"henrywong","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/56257d5353428bab1d80ae29b9da9fb3","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":2,"tweetSize":30,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖(非转发)","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.11","exceedPercentage":"93.23%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.25","exceedPercentage":"93.93%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":7,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":630877408,"gmtCreate":1642789463215,"gmtModify":1642789463328,"author":{"id":"3584951930259825","authorId":"3584951930259825","name":"Henrywong","avatar":"https://static.tigerbbs.com/56257d5353428bab1d80ae29b9da9fb3","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"It is completely wrong logic for stock options to drive stock price. Over trading in stock options has now become a problem ","listText":"It is completely wrong logic for stock options to drive stock price. Over trading in stock options has now become a problem ","text":"It is completely wrong logic for stock options to drive stock price. Over trading in stock options has now become a problem","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/630877408","repostId":"1165558393","repostType":4,"repost":{"id":"1165558393","pubTimestamp":1642778100,"share":"https://www.laohu8.com/m/news/1165558393?lang=&edition=full","pubTime":"2022-01-21 23:15","market":"us","language":"en","title":"A $3.3 Trillion Expiry of Stock Options Adds to Market Jitters","url":"https://stock-news.laohu8.com/highlight/detail?id=1165558393","media":"Bloomberg","summary":"Third Friday of each month brings wave of derivatives activityPotential rate rises, Netflix among fa","content":"<html><head></head><body><ul><li>Third Friday of each month brings wave of derivatives activity</li><li>Potential rate rises, Netflix among factors driving volatility</li></ul><p>Aside from the rout in stay-at-home stocks and gyrations in bonds lurks another key force behind the market turbulence this week: More than $3 trillion of expiring stock options.</p><p>The phenomenon -- generally known as OpEx -- has taken place like clockwork for about a year now. Around the middle of most months, American equities lurch lower, usually near the third Friday -- the day that most stock derivatives expire.</p><p>The dynamic has been blamed on dealers in the options market balancing their exposures by buying and selling underlying stocks or index futures. And this month’s OpEx is a big one.</p><p>All told, Goldman Sachs Group Inc. estimates about $3.3 trillion of U.S. equity derivatives are set to expire Friday. That includes roughly $1.3 trillion across single stocks, the firm said. About $1 trillion of S&P 500-linked contracts will run out, and $240 billion in options tied to the world’s largest ETF, the SPDR S&P 500 ETF Trust (tickerSPY).</p><p>Options are not the only driver of stocks, of course, and there is plenty of uncertainty around their influence. But they may have added to volatility as the likes of Netflix Inc. and Peloton Interactive Inc. slumped on miserable outlooks while the rates-driven rout tightened its grip on pricey growth stocks.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/55fbe02b679fcb2143196699f1fe5dc4\" tg-width=\"1200\" tg-height=\"675\" width=\"100%\" height=\"auto\"/><span>White circles indicate approximate OpEx days. Source: Bloomberg.</span></p><p>“Today’s expiry could be important for stocks with large open interest in at-the-money (ATM) options,” Goldman strategists including Vishal Vivek wrote in a note. “Market makers’ delta-hedging large options portfolios will be active. This flow is likely to dampen volatility in some names while exacerbating stock price moves in others.”</p><p>This OpEx dynamic is far from new, but it’s thought to be growing alongside the boom in options trading. A surge in retail investor participation in the market and rising hedging by institutional pros have spurred an increase in dealer activity.</p><p>This dynamic has become so large that some speculate the relationship between stocks and options has been upended, with derivatives now driving the equity market instead of vice versa.</p><p>Brent Kochuba, founder of analytic service SpotGamma, observed that last week and earlier this week, the existence of many large in-the-money single-stock call positions had led to a large positive delta skew -- the theoretical value of stock required for market makers to hedge the directional exposure resulting from all options activity. As most of these positions closed, that has contributed to recent market volatility. Now, Friday’s expiration has a relatively flat delta position.</p><p>In other words, dealer exposure is now close to neutral, so the effects of the expiry should ease.</p><p>“Call have been closed, puts have been purchased and stock prices have dropped precipitously,” Kochuba said. “As a result of this shift, we think that some of the selling in single stocks may now subside as we head into Wednesday’s FOMC.”</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cdc4ff45ecdfd4246fdadad5105bc95a\" tg-width=\"1200\" tg-height=\"665\" width=\"100%\" height=\"auto\"/><span>Source: Goldman Sachs</span></p><p>The process works roughly like this: When an investor buys or sells an option, the other side of that trade is taken up by a market maker. These dealers like to neutralize their exposure, which they do by trading the underlying.</p><p>In the run-up to expiration, depending on where dealers’ overall positions are, they can act as a stabilizing force or a volatility accelerator.</p><p>However, it’s a complicated picture, and the exact dynamics depend on the options expiring, new ones created and moves in the underlying assets.</p><p><img src=\"https://static.tigerbbs.com/500da097353cbf29257d826eac4a3f2d\" tg-width=\"1200\" tg-height=\"675\" width=\"100%\" height=\"auto\"/></p><p>U.S. stocks have already endured a tumultuous start to 2022.</p><p>The Cboe Volatility Index, a measure of expected price swings in the S&P 500 known as the VIX, has jumped about 10 points to 27 points since the start of the month. Investors are adjusting to the prospect of tighter monetary policy by ditching expensive-looking stocks, and those whose expected profits are far in the future.</p><p>The three main equity gauges dropped again on Friday morning as of 9:44 a.m. in New York.</p><p>“Is options expiration a contributor to the selloff? Yes. Is it the prime driver? No,” said Chris Murphy, co-head of derivatives strategy at Susquehanna International Group. “The Fed and deleveraging is the reason for the selloff.”</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A $3.3 Trillion Expiry of Stock Options Adds to Market Jitters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA $3.3 Trillion Expiry of Stock Options Adds to Market Jitters\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-21 23:15 GMT+8 <a href=https://www.bloomberg.com/news/articles/2022-01-21/a-3-3-trillion-expiry-of-stock-options-adds-to-market-jitters?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Third Friday of each month brings wave of derivatives activityPotential rate rises, Netflix among factors driving volatilityAside from the rout in stay-at-home stocks and gyrations in bonds lurks ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-01-21/a-3-3-trillion-expiry-of-stock-options-adds-to-market-jitters?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://www.bloomberg.com/news/articles/2022-01-21/a-3-3-trillion-expiry-of-stock-options-adds-to-market-jitters?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165558393","content_text":"Third Friday of each month brings wave of derivatives activityPotential rate rises, Netflix among factors driving volatilityAside from the rout in stay-at-home stocks and gyrations in bonds lurks another key force behind the market turbulence this week: More than $3 trillion of expiring stock options.The phenomenon -- generally known as OpEx -- has taken place like clockwork for about a year now. Around the middle of most months, American equities lurch lower, usually near the third Friday -- the day that most stock derivatives expire.The dynamic has been blamed on dealers in the options market balancing their exposures by buying and selling underlying stocks or index futures. And this month’s OpEx is a big one.All told, Goldman Sachs Group Inc. estimates about $3.3 trillion of U.S. equity derivatives are set to expire Friday. That includes roughly $1.3 trillion across single stocks, the firm said. About $1 trillion of S&P 500-linked contracts will run out, and $240 billion in options tied to the world’s largest ETF, the SPDR S&P 500 ETF Trust (tickerSPY).Options are not the only driver of stocks, of course, and there is plenty of uncertainty around their influence. But they may have added to volatility as the likes of Netflix Inc. and Peloton Interactive Inc. slumped on miserable outlooks while the rates-driven rout tightened its grip on pricey growth stocks.White circles indicate approximate OpEx days. Source: Bloomberg.“Today’s expiry could be important for stocks with large open interest in at-the-money (ATM) options,” Goldman strategists including Vishal Vivek wrote in a note. “Market makers’ delta-hedging large options portfolios will be active. This flow is likely to dampen volatility in some names while exacerbating stock price moves in others.”This OpEx dynamic is far from new, but it’s thought to be growing alongside the boom in options trading. A surge in retail investor participation in the market and rising hedging by institutional pros have spurred an increase in dealer activity.This dynamic has become so large that some speculate the relationship between stocks and options has been upended, with derivatives now driving the equity market instead of vice versa.Brent Kochuba, founder of analytic service SpotGamma, observed that last week and earlier this week, the existence of many large in-the-money single-stock call positions had led to a large positive delta skew -- the theoretical value of stock required for market makers to hedge the directional exposure resulting from all options activity. As most of these positions closed, that has contributed to recent market volatility. Now, Friday’s expiration has a relatively flat delta position.In other words, dealer exposure is now close to neutral, so the effects of the expiry should ease.“Call have been closed, puts have been purchased and stock prices have dropped precipitously,” Kochuba said. “As a result of this shift, we think that some of the selling in single stocks may now subside as we head into Wednesday’s FOMC.”Source: Goldman SachsThe process works roughly like this: When an investor buys or sells an option, the other side of that trade is taken up by a market maker. These dealers like to neutralize their exposure, which they do by trading the underlying.In the run-up to expiration, depending on where dealers’ overall positions are, they can act as a stabilizing force or a volatility accelerator.However, it’s a complicated picture, and the exact dynamics depend on the options expiring, new ones created and moves in the underlying assets.U.S. stocks have already endured a tumultuous start to 2022.The Cboe Volatility Index, a measure of expected price swings in the S&P 500 known as the VIX, has jumped about 10 points to 27 points since the start of the month. Investors are adjusting to the prospect of tighter monetary policy by ditching expensive-looking stocks, and those whose expected profits are far in the future.The three main equity gauges dropped again on Friday morning as of 9:44 a.m. in New York.“Is options expiration a contributor to the selloff? Yes. Is it the prime driver? No,” said Chris Murphy, co-head of derivatives strategy at Susquehanna International Group. “The Fed and deleveraging is the reason for the selloff.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":697900865,"gmtCreate":1642183149112,"gmtModify":1642183149204,"author":{"id":"3584951930259825","authorId":"3584951930259825","name":"Henrywong","avatar":"https://static.tigerbbs.com/56257d5353428bab1d80ae29b9da9fb3","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"People are dreaming and think that electric car are flying out of the showrooms. Elon Musk certainly has successfully build your dream more than BYD","listText":"People are dreaming and think that electric car are flying out of the showrooms. Elon Musk certainly has successfully build your dream more than BYD","text":"People are dreaming and think that electric car are flying out of the showrooms. Elon Musk certainly has successfully build your dream more than BYD","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/697900865","repostId":"2203126977","repostType":4,"repost":{"id":"2203126977","pubTimestamp":1642174200,"share":"https://www.laohu8.com/m/news/2203126977?lang=&edition=full","pubTime":"2022-01-14 23:30","market":"us","language":"en","title":"Are Electric Vehicle Stocks Overhyped?","url":"https://stock-news.laohu8.com/highlight/detail?id=2203126977","media":"Motley Fool","summary":"The short answer: Almost definitely.","content":"<html><head></head><body><p>The excitement around electric vehicle stocks is palpable. From <b>Rivian</b> (NASDAQ:RIVN) at a $76 billion market cap with no revenue to <b>Tesla</b> (NASDAQ:TSLA) breaching a $1.1 trillion market cap when it was valued under $100 billion less than three years ago, many investors are bullish on the opportunity in electric vehicles.</p><p>And why wouldn't they be? The industry is growing quickly, up 26% year over year from 2020, and is going after a gigantic market opportunity in the worldwide car market. But just because these stocks are in a large, growing industry doesn't mean they will be great investments over the next decade. Just ask <b>Cisco Systems</b> investors who bought stock in 1999 and 2000.</p><p>Are electric vehicle stocks overhyped? Yes. Let me explain why.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/90344f91dac6378d78934846de60ce59\" tg-width=\"700\" tg-height=\"465\" referrerpolicy=\"no-referrer\"/><span>Image source: Getty Images.</span></p><h2>Growth is strong, and the market opportunity is massive</h2><p>To start out, let's give some context around the global opportunity in electric vehicles and the overall automotive industry. In 2021, it is estimated that 6.4 million electric vehicles (EVs) were sold around the world, of which 4 million of these were all-electric and 2.4 million plug-in hybrids. That total number is up 26% from 2020.</p><p>In 2022, analysts are actually expecting this growth to accelerate due to the number of models being available in the U.S. jumping from 62 to 100. If that is the case, global annual sales for electric vehicles should hit 10 million in the near future. For reference, 66 million total cars are estimated to have been sold around the world in 2021.</p><p>Those are all high-level numbers, but what about the financial opportunity? Assuming an average selling price of $25,000, 10 million EV sales would equate to $250 billion in annual sales. At 50 million EVs, which assumes they take over the majority of the auto market, that equates to $1.25 trillion in sales. Clearly, the opportunity is massive from a revenue standpoint.</p><h2>Margins will be low</h2><p>While the revenue opportunity for EVs is large, these manufacturing businesses also have low margins. For example, let's look at <b>Toyota </b>(NYSE:TM), the largest automaker in the world, with an estimated 8.5% market share in 2019. Over the last 12 months, the company has brought in $281 billion in revenue. On that revenue, only $31 billion turned into operating income, or an 11% operating margin.</p><p>Tesla, the biggest pure-play EV maker, is seeing just shy of 10% operating margins on $47 billion in revenue. Given the reduction in manufacturing complications of a battery pack versus an internal combustion engine, EV makers may achieve better operating margins than 11% at scale. But they still require bending metal to succeed, so the likelihood they will be much higher than 11% on average over the long term seems unlikely.</p><p>What's more, automotive businesses require tons of capital expenditures relative to their sales just to stay afloat. For example, Toyota spent almost $35 billion on capital investments over the last 12 months. Given its profit margins, that makes it very difficult for the company to return excess cash to shareholders -- which is the <i>only</i> driver of shareholder value in the long run. This is why Toyota's stock historically trades at a price-to-earnings (P/E) ratio at or around 10. And EV stocks will have a similar fate due to this capital intensity.</p><h2>Expectations are too high</h2><p>Let's move back to our revenue example. If annual EV sales reach $1.25 trillion and we assign a generous 15% operating margin across the industry, there will be $180 billion in annual operating income once EV sales hit 50 million a year. Remember, sales are currently at only 6.4 million, including plug-in hybrids, so this is a long way off. On that $180 billion in operating income, if you give it a 21% corporate tax rate, that is $142.2 billion in annual net income across the industry.</p><p>Put an average P/E of 10 (remember, this is typical for automotive companies because of the capital intensity) on the stocks, and you have $1.42 trillion in combined market value once EVs reach maturity. Looking at the five pure-play EV stocks right now, which are Tesla, Rivian, <b>Lucid Motors </b>(NASDAQ:LCID), <b>Nio </b>(NYSE:NIO), and <b>Xpeng </b>(NYSE:XPEV), their combined market caps are <i>currently</i> $1.34 trillion, or pretty darn close to what the whole industry will be worth at maturity with optimistic margin and growth assumptions.</p><p>And this doesn't include the legacy automakers like Toyota, <b>Ford Motor Company</b>, <b>GM</b>, and <b>Volkswagen</b>, which are all making major investments into EVs. Assuming none of these legacy manufacturers will at least capture some of the $1.42 trillion market value is naive, in my opinion.</p><p>Given all these numbers, it is clear that the electric vehicle market is overhyped. If you are invested in <a href=\"https://laohu8.com/S/AONE.U\">one</a> of these companies, or even a legacy automaker, you need to be confident in that specific company's ability to win market share and beat all these competitors. If that doesn't happen, it is likely your investment will go very poorly over the next decade.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Electric Vehicle Stocks Overhyped?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Electric Vehicle Stocks Overhyped?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-14 23:30 GMT+8 <a href=https://www.fool.com/investing/2022/01/14/are-electric-vehicle-stocks-overhyped-tesla/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The excitement around electric vehicle stocks is palpable. From Rivian (NASDAQ:RIVN) at a $76 billion market cap with no revenue to Tesla (NASDAQ:TSLA) breaching a $1.1 trillion market cap when it was...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/14/are-electric-vehicle-stocks-overhyped-tesla/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","RIVN":"Rivian Automotive, Inc.","NIO":"蔚来","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","BK4509":"腾讯概念","BK4525":"远程办公概念","BK4527":"明星科技股","BK4020":"通信设备","BK4550":"红杉资本持仓","BK4526":"热门中概股","LCID":"Lucid Group Inc","BK4551":"寇图资本持仓","BK4505":"高瓴资本持仓","BK4560":"网络安全概念","BK4504":"桥水持仓","BK4099":"汽车制造商","BK4548":"巴美列捷福持仓","CSCO":"思科","TSLA":"特斯拉","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","XPEV":"小鹏汽车","BK4531":"中概回港概念","TM":"丰田汽车"},"source_url":"https://www.fool.com/investing/2022/01/14/are-electric-vehicle-stocks-overhyped-tesla/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2203126977","content_text":"The excitement around electric vehicle stocks is palpable. From Rivian (NASDAQ:RIVN) at a $76 billion market cap with no revenue to Tesla (NASDAQ:TSLA) breaching a $1.1 trillion market cap when it was valued under $100 billion less than three years ago, many investors are bullish on the opportunity in electric vehicles.And why wouldn't they be? The industry is growing quickly, up 26% year over year from 2020, and is going after a gigantic market opportunity in the worldwide car market. But just because these stocks are in a large, growing industry doesn't mean they will be great investments over the next decade. Just ask Cisco Systems investors who bought stock in 1999 and 2000.Are electric vehicle stocks overhyped? Yes. Let me explain why.Image source: Getty Images.Growth is strong, and the market opportunity is massiveTo start out, let's give some context around the global opportunity in electric vehicles and the overall automotive industry. In 2021, it is estimated that 6.4 million electric vehicles (EVs) were sold around the world, of which 4 million of these were all-electric and 2.4 million plug-in hybrids. That total number is up 26% from 2020.In 2022, analysts are actually expecting this growth to accelerate due to the number of models being available in the U.S. jumping from 62 to 100. If that is the case, global annual sales for electric vehicles should hit 10 million in the near future. For reference, 66 million total cars are estimated to have been sold around the world in 2021.Those are all high-level numbers, but what about the financial opportunity? Assuming an average selling price of $25,000, 10 million EV sales would equate to $250 billion in annual sales. At 50 million EVs, which assumes they take over the majority of the auto market, that equates to $1.25 trillion in sales. Clearly, the opportunity is massive from a revenue standpoint.Margins will be lowWhile the revenue opportunity for EVs is large, these manufacturing businesses also have low margins. For example, let's look at Toyota (NYSE:TM), the largest automaker in the world, with an estimated 8.5% market share in 2019. Over the last 12 months, the company has brought in $281 billion in revenue. On that revenue, only $31 billion turned into operating income, or an 11% operating margin.Tesla, the biggest pure-play EV maker, is seeing just shy of 10% operating margins on $47 billion in revenue. Given the reduction in manufacturing complications of a battery pack versus an internal combustion engine, EV makers may achieve better operating margins than 11% at scale. But they still require bending metal to succeed, so the likelihood they will be much higher than 11% on average over the long term seems unlikely.What's more, automotive businesses require tons of capital expenditures relative to their sales just to stay afloat. For example, Toyota spent almost $35 billion on capital investments over the last 12 months. Given its profit margins, that makes it very difficult for the company to return excess cash to shareholders -- which is the only driver of shareholder value in the long run. This is why Toyota's stock historically trades at a price-to-earnings (P/E) ratio at or around 10. And EV stocks will have a similar fate due to this capital intensity.Expectations are too highLet's move back to our revenue example. If annual EV sales reach $1.25 trillion and we assign a generous 15% operating margin across the industry, there will be $180 billion in annual operating income once EV sales hit 50 million a year. Remember, sales are currently at only 6.4 million, including plug-in hybrids, so this is a long way off. On that $180 billion in operating income, if you give it a 21% corporate tax rate, that is $142.2 billion in annual net income across the industry.Put an average P/E of 10 (remember, this is typical for automotive companies because of the capital intensity) on the stocks, and you have $1.42 trillion in combined market value once EVs reach maturity. Looking at the five pure-play EV stocks right now, which are Tesla, Rivian, Lucid Motors (NASDAQ:LCID), Nio (NYSE:NIO), and Xpeng (NYSE:XPEV), their combined market caps are currently $1.34 trillion, or pretty darn close to what the whole industry will be worth at maturity with optimistic margin and growth assumptions.And this doesn't include the legacy automakers like Toyota, Ford Motor Company, GM, and Volkswagen, which are all making major investments into EVs. Assuming none of these legacy manufacturers will at least capture some of the $1.42 trillion market value is naive, in my opinion.Given all these numbers, it is clear that the electric vehicle market is overhyped. If you are invested in one of these companies, or even a legacy automaker, you need to be confident in that specific company's ability to win market share and beat all these competitors. If that doesn't happen, it is likely your investment will go very poorly over the next decade.","news_type":1},"isVote":1,"tweetType":1,"viewCount":629,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694447679,"gmtCreate":1642090581000,"gmtModify":1642090581000,"author":{"id":"3584951930259825","authorId":"3584951930259825","name":"Henrywong","avatar":"https://static.tigerbbs.com/56257d5353428bab1d80ae29b9da9fb3","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Start flying high","listText":"Start flying high","text":"Start flying high","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/694447679","repostId":"1105224732","repostType":4,"isVote":1,"tweetType":1,"viewCount":1075,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691257512,"gmtCreate":1640215263910,"gmtModify":1640215263910,"author":{"id":"3584951930259825","authorId":"3584951930259825","name":"Henrywong","avatar":"https://static.tigerbbs.com/56257d5353428bab1d80ae29b9da9fb3","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691257512","repostId":"2193192720","repostType":4,"repost":{"id":"2193192720","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640185119,"share":"https://www.laohu8.com/m/news/2193192720?lang=&edition=full","pubTime":"2021-12-22 22:58","market":"us","language":"en","title":"Tesla, authorities submit documents for German plant approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2193192720","media":"Reuters","summary":"BERLIN, Dec 22 - Tesla and relevant authorities have submitted all the documents necessary for the approval process for its planned factory near Berlin, the environment ministry of the German state of Brandenburg said on Wednesday.The approval process is still ongoing, the ministry said.Tesla could not be immediately reached for comment.Due to environmental resistance and red tape, it remained unclear when the first vehicles will roll off the production line at the site. Brandenburg premier Die","content":"<p>BERLIN, Dec 22 (Reuters) - Tesla and relevant authorities have submitted all the documents necessary for the approval process for its planned factory near Berlin, the environment ministry of the German state of Brandenburg said on Wednesday.</p>\n<p>The approval process is still ongoing, the ministry said.</p>\n<p>Tesla could not be immediately reached for comment.</p>\n<p>Due to environmental resistance and red tape, it remained unclear when the first vehicles will roll off the production line at the site. Brandenburg premier Dietmar Woidke had recently suggested a decision might come in early 2022.</p>\n<p>Tesla has repeatedly had to push back the expected opening of the factory and Chief Executive Elon Musk has regularly travelled to Germany to check on the plant's progress, criticising German bureaucracy for slowing down construction.</p>\n<p>Since Tesla expanded its original proposal to include a battery factory, the construction plans had to undergo a renewed process of public consultation which ended on Nov. 22.</p>\n<p>The response to all objections raised in that consultation is a prerequisite for a final building permit.</p>\n<p>Currently, Tesla is only working on the factory on the basis of preliminary building permits.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla, authorities submit documents for German plant approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla, authorities submit documents for German plant approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-22 22:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BERLIN, Dec 22 (Reuters) - Tesla and relevant authorities have submitted all the documents necessary for the approval process for its planned factory near Berlin, the environment ministry of the German state of Brandenburg said on Wednesday.</p>\n<p>The approval process is still ongoing, the ministry said.</p>\n<p>Tesla could not be immediately reached for comment.</p>\n<p>Due to environmental resistance and red tape, it remained unclear when the first vehicles will roll off the production line at the site. Brandenburg premier Dietmar Woidke had recently suggested a decision might come in early 2022.</p>\n<p>Tesla has repeatedly had to push back the expected opening of the factory and Chief Executive Elon Musk has regularly travelled to Germany to check on the plant's progress, criticising German bureaucracy for slowing down construction.</p>\n<p>Since Tesla expanded its original proposal to include a battery factory, the construction plans had to undergo a renewed process of public consultation which ended on Nov. 22.</p>\n<p>The response to all objections raised in that consultation is a prerequisite for a final building permit.</p>\n<p>Currently, Tesla is only working on the factory on the basis of preliminary building permits.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","BK4527":"明星科技股","TSLA":"特斯拉","BK4534":"瑞士信贷持仓","BK4555":"新能源车","BK4099":"汽车制造商","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4548":"巴美列捷福持仓","BK4550":"红杉资本持仓"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193192720","content_text":"BERLIN, Dec 22 (Reuters) - Tesla and relevant authorities have submitted all the documents necessary for the approval process for its planned factory near Berlin, the environment ministry of the German state of Brandenburg said on Wednesday.\nThe approval process is still ongoing, the ministry said.\nTesla could not be immediately reached for comment.\nDue to environmental resistance and red tape, it remained unclear when the first vehicles will roll off the production line at the site. Brandenburg premier Dietmar Woidke had recently suggested a decision might come in early 2022.\nTesla has repeatedly had to push back the expected opening of the factory and Chief Executive Elon Musk has regularly travelled to Germany to check on the plant's progress, criticising German bureaucracy for slowing down construction.\nSince Tesla expanded its original proposal to include a battery factory, the construction plans had to undergo a renewed process of public consultation which ended on Nov. 22.\nThe response to all objections raised in that consultation is a prerequisite for a final building permit.\nCurrently, Tesla is only working on the factory on the basis of preliminary building permits.","news_type":1},"isVote":1,"tweetType":1,"viewCount":887,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691254441,"gmtCreate":1640215198079,"gmtModify":1640215198079,"author":{"id":"3584951930259825","authorId":"3584951930259825","name":"Henrywong","avatar":"https://static.tigerbbs.com/56257d5353428bab1d80ae29b9da9fb3","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691254441","repostId":"2193192429","repostType":4,"repost":{"id":"2193192429","pubTimestamp":1640185620,"share":"https://www.laohu8.com/m/news/2193192429?lang=&edition=full","pubTime":"2021-12-22 23:07","market":"us","language":"en","title":"Netflix Rally in 2022 Hinges on Finding the Next ‘Squid Game’","url":"https://stock-news.laohu8.com/highlight/detail?id=2193192429","media":"Bloomberg","summary":" -- Fast-growing technology stocks have taken a beating in recent weeks -- and Netflix Inc. is no exception.Shares of the streaming giant are down 13% from a Nov. 17 record, in tandem with the slump in the tech-heavy Nasdaq 100 Stock Index after the Federal Reserve indicated three rate increases and faster tapering in 2022. Concerns over the omicron coronavirus variant have also pressured equities.These forces have thrown the broad investment outlook for the start of 2022 into flux, but what has","content":"<p>(Bloomberg) -- Fast-growing technology stocks have taken a beating in recent weeks -- and Netflix Inc. is no exception.</p>\n<p>Shares of the streaming giant are down 13% from a Nov. 17 record, in tandem with the slump in the tech-heavy Nasdaq 100 Stock Index after the Federal Reserve indicated three rate increases and faster tapering in 2022. Concerns over the omicron coronavirus variant have also pressured equities.</p>\n<p>These forces have thrown the broad investment outlook for the start of 2022 into flux, but what hasn’t changed is the bullish view on Netflix shares. Wall Street’s optimism hinges on the company’s ability to lure new subscribers with best-in-class content, boosting margins and cash flow along the way.</p>\n<p>The 12-month average analyst price target comes in at $683, which implies a 13% gain from Tuesday’s closing price of $604.92. That’s less than the 28% increase analysts project for streaming rival Walt Disney Co., but it would extend Netflix’s streak of double-digit annual gains.</p>\n<p>“Despite market turbulence, we’re still interested in having exposure to tech companies,” said Erica Furfaro, senior portfolio analyst at ClearBridge Investments, which holds Netflix shares. “Even in a rising rate environment, being invested behind the best growth winners is still a prudent approach.”</p>\n<p>Netflix this year defied skeptics who fretted that it might stall as the world began to open up from lockdowns. After falling in the first half, the stock climbed to fresh highs on the unexpected success of South Korean show “Squid Game,” which became Netflix’s biggest series launch ever.</p>\n<p>Shares had already started to climb in early August, with the stock riding a three-month, 33% rally as Wall Street began to appreciate the slew of shows and movies coming in the third and fourth quarters, including new seasons of “Money Heist” and “Sex Education,” said Wells Fargo Securities analyst Steven Cahall.</p>\n<p>Cahall is among analysts that expect Netflix’s rally will continue, projecting that the stock will reach $800 by the end of 2022. <a href=\"https://laohu8.com/S/BPOPN\">Popular</a> content, subscriber growth and margin expansion -- the longstanding yardsticks for the company -- will remain the catalysts for shares, he said.</p>\n<p>“All the revenue is based on content,” Cahall said in an interview. “The content is the majority of their costs. And so their ability to spend on content and generate new content is really what drives these business models.”</p>\n<p><b>Fierce Competition</b></p>\n<p>For Mark Stoeckle, chief executive officer and senior portfolio manager at Adams Funds, Netflix’s valuation and streaming competition are two factors that are keeping him from turning more bullish on the stock. The Adams Diversified Equity Fund is modestly overweight Netflix versus the S&P 500 Index after buying shares in September.</p>\n<p>Netflix trades around 46 times forward earnings. Although that’s down from a recent peak of nearly 54 times in October, it still tops the Nasdaq 100 at 28 times and the S&P 500 Communication Services Index at 19.6 times.</p>\n<p>Disney, whose flagship streaming service is widely seen as Netflix’s biggest competitor, has tumbled amid concerns that subscriber growth at Disney+ is slowing and as the variant threatens a return to theme parks. The stock is heading for its first annual decline since 2016 and its worst year since 2008.</p>\n<p>Both Netflix and Disney face competition in 2022 from the direct-to-consumer service that will emerge from the merger of Discovery Inc. and AT&T Inc.’s WarnerMedia, according to <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a> analyst Tim Nollen. Last month, he upgraded Discovery to outperform from neutral in anticipation of the deal which he said will create “<a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most broad-based content offerings.” He’s neutral on Netflix on valuation and rates Disney outperform based in part on an eventual rebound at its parks and the box office.</p>\n<p>But ultimately, it’s nearly all about content, analysts say. The slate for 2022 includes new seasons for some of its biggest hits, including “Stranger Things” and “Bridgerton.”</p>\n<p>“I hate to say that these big media companies are just still in the hit business, but they are,” Cahall said.</p>\n<p><b>Buying Opportunities</b></p>\n<p>Selloffs are part of the equation, according to David Klink, senior equity analyst at Huntington National Bank, but he views them as buying opportunities for Netflix shares. Huntington Private Bank’s internal growth strategy added to its position in late November, he said.</p>\n<p>Klink had been worried that Netflix and other companies that were popular plays during Covid-19 lockdowns would struggle in 2021 as they faced tough year-over-year comparisons. Netflix proved those fears were overblown. It’s on track to notch a 12% advance for 2021 in what would be the stock’s seventh straight year of gains -- even with the most recent slump.</p>\n<p>“There’s rarely a year where there’s not a 10 or 15% drawdown, but you’re generally better off holding it,” Klink said.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Netflix Rally in 2022 Hinges on Finding the Next ‘Squid Game’</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNetflix Rally in 2022 Hinges on Finding the Next ‘Squid Game’\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 23:07 GMT+8 <a href=https://finance.yahoo.com/news/netflix-rally-2022-hinges-finding-120000844.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Fast-growing technology stocks have taken a beating in recent weeks -- and Netflix Inc. is no exception.\nShares of the streaming giant are down 13% from a Nov. 17 record, in tandem with...</p>\n\n<a href=\"https://finance.yahoo.com/news/netflix-rally-2022-hinges-finding-120000844.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NFLX":"奈飞","QNETCN":"纳斯达克中美互联网老虎指数","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4524":"宅经济概念","BK4534":"瑞士信贷持仓","DIS":"迪士尼","BK4108":"电影和娱乐","BK4527":"明星科技股","BK4507":"流媒体概念"},"source_url":"https://finance.yahoo.com/news/netflix-rally-2022-hinges-finding-120000844.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2193192429","content_text":"(Bloomberg) -- Fast-growing technology stocks have taken a beating in recent weeks -- and Netflix Inc. is no exception.\nShares of the streaming giant are down 13% from a Nov. 17 record, in tandem with the slump in the tech-heavy Nasdaq 100 Stock Index after the Federal Reserve indicated three rate increases and faster tapering in 2022. Concerns over the omicron coronavirus variant have also pressured equities.\nThese forces have thrown the broad investment outlook for the start of 2022 into flux, but what hasn’t changed is the bullish view on Netflix shares. Wall Street’s optimism hinges on the company’s ability to lure new subscribers with best-in-class content, boosting margins and cash flow along the way.\nThe 12-month average analyst price target comes in at $683, which implies a 13% gain from Tuesday’s closing price of $604.92. That’s less than the 28% increase analysts project for streaming rival Walt Disney Co., but it would extend Netflix’s streak of double-digit annual gains.\n“Despite market turbulence, we’re still interested in having exposure to tech companies,” said Erica Furfaro, senior portfolio analyst at ClearBridge Investments, which holds Netflix shares. “Even in a rising rate environment, being invested behind the best growth winners is still a prudent approach.”\nNetflix this year defied skeptics who fretted that it might stall as the world began to open up from lockdowns. After falling in the first half, the stock climbed to fresh highs on the unexpected success of South Korean show “Squid Game,” which became Netflix’s biggest series launch ever.\nShares had already started to climb in early August, with the stock riding a three-month, 33% rally as Wall Street began to appreciate the slew of shows and movies coming in the third and fourth quarters, including new seasons of “Money Heist” and “Sex Education,” said Wells Fargo Securities analyst Steven Cahall.\nCahall is among analysts that expect Netflix’s rally will continue, projecting that the stock will reach $800 by the end of 2022. Popular content, subscriber growth and margin expansion -- the longstanding yardsticks for the company -- will remain the catalysts for shares, he said.\n“All the revenue is based on content,” Cahall said in an interview. “The content is the majority of their costs. And so their ability to spend on content and generate new content is really what drives these business models.”\nFierce Competition\nFor Mark Stoeckle, chief executive officer and senior portfolio manager at Adams Funds, Netflix’s valuation and streaming competition are two factors that are keeping him from turning more bullish on the stock. The Adams Diversified Equity Fund is modestly overweight Netflix versus the S&P 500 Index after buying shares in September.\nNetflix trades around 46 times forward earnings. Although that’s down from a recent peak of nearly 54 times in October, it still tops the Nasdaq 100 at 28 times and the S&P 500 Communication Services Index at 19.6 times.\nDisney, whose flagship streaming service is widely seen as Netflix’s biggest competitor, has tumbled amid concerns that subscriber growth at Disney+ is slowing and as the variant threatens a return to theme parks. The stock is heading for its first annual decline since 2016 and its worst year since 2008.\nBoth Netflix and Disney face competition in 2022 from the direct-to-consumer service that will emerge from the merger of Discovery Inc. and AT&T Inc.’s WarnerMedia, according to Macquarie analyst Tim Nollen. Last month, he upgraded Discovery to outperform from neutral in anticipation of the deal which he said will create “one of the most broad-based content offerings.” He’s neutral on Netflix on valuation and rates Disney outperform based in part on an eventual rebound at its parks and the box office.\nBut ultimately, it’s nearly all about content, analysts say. The slate for 2022 includes new seasons for some of its biggest hits, including “Stranger Things” and “Bridgerton.”\n“I hate to say that these big media companies are just still in the hit business, but they are,” Cahall said.\nBuying Opportunities\nSelloffs are part of the equation, according to David Klink, senior equity analyst at Huntington National Bank, but he views them as buying opportunities for Netflix shares. Huntington Private Bank’s internal growth strategy added to its position in late November, he said.\nKlink had been worried that Netflix and other companies that were popular plays during Covid-19 lockdowns would struggle in 2021 as they faced tough year-over-year comparisons. Netflix proved those fears were overblown. It’s on track to notch a 12% advance for 2021 in what would be the stock’s seventh straight year of gains -- even with the most recent slump.\n“There’s rarely a year where there’s not a 10 or 15% drawdown, but you’re generally better off holding it,” Klink said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":741,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691254646,"gmtCreate":1640215147121,"gmtModify":1640215147121,"author":{"id":"3584951930259825","authorId":"3584951930259825","name":"Henrywong","avatar":"https://static.tigerbbs.com/56257d5353428bab1d80ae29b9da9fb3","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691254646","repostId":"1158266085","repostType":4,"repost":{"id":"1158266085","pubTimestamp":1640214329,"share":"https://www.laohu8.com/m/news/1158266085?lang=&edition=full","pubTime":"2021-12-23 07:05","market":"us","language":"en","title":"Tesla’s Touch-Screen Gaming Probed by U.S. Auto-Safety Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=1158266085","media":"The Wall Street Journal","summary":"The National Highway Traffic Safety Administration says the screen may distract drivers\nVince Patton","content":"<p>The National Highway Traffic Safety Administration says the screen may distract drivers</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f13c4a406aeab8eaadfbbe4fa762a26f\" tg-width=\"1290\" tg-height=\"860\" width=\"100%\" height=\"auto\"><span>Vince Patton, a new Tesla owner, shows how he can play videogames while driving on a closed course in Portland earlier this month.</span></p>\n<p>The top U.S. auto-safety regulator has opened an investigation into a Tesla Inc. feature that allows people—including the driver—to play games on a touch screen while the vehicle is in motion.</p>\n<p>The ability to play games while driving has been available for roughly a year in some vehicles and “may distract the driver and increase the risk of a crash,” the National Highway Traffic Safety Administration said in a document made public Wednesday. The feature previously was only enabled while vehicles were in park, the agency said, adding it launched the probe to evaluate the potential for driver distraction.</p>\n<p>The probe covers about 580,000 Tesla vehicles of all types and model years 2017 to present in some cases, NHTSA said.</p>\n<p>Tesla didn’t immediately respond to a request for comment.</p>\n<p>When a vehicle is in drive, Tesla asks those seeking to play games on the centrally located front touch screen to confirm they are a passenger. Available games include solitaire, Sky Force Reloaded and The Battle of Polytopia. Certain other games aren’t available unless the vehicle is parked.</p>\n<p>NHTSA said it wasn’t aware of any crashes or injuries linked to the feature. The agency received a complaint about the functionality earlier this year that urged the regulator to prohibit live video and interactive web browsing on the centrally located front touch screen while Teslas are in motion.</p>\n<p>Tesla Chief Executive Elon Musk has said he thinks entertainment will be highly desired once vehicles become autonomous. Tesla’s advanced driver-assistance system, known as Autopilot, doesn’t make vehicles autonomous.</p>\n<p><img src=\"https://static.tigerbbs.com/a798015f792f0f3e9247f60cab46c81e\" tg-width=\"412\" tg-height=\"451\" width=\"100%\" height=\"auto\"></p>\n<p>NHTSA investigations can lead to recalls. Tesla recalled roughly 135,000 vehicles earlier this year over touch-screen failures after NHTSA urged it to do so.</p>\n<p>The agency is also investigating Tesla’s Autopilot system after a series of crashes involving Teslas and one or more parked emergency vehicles.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla’s Touch-Screen Gaming Probed by U.S. Auto-Safety Regulator</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla’s Touch-Screen Gaming Probed by U.S. Auto-Safety Regulator\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 07:05 GMT+8 <a href=https://www.wsj.com/articles/teslas-touch-screen-gaming-probed-by-u-s-auto-safety-regulator-11640187212?mod=hp_lista_pos5><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The National Highway Traffic Safety Administration says the screen may distract drivers\nVince Patton, a new Tesla owner, shows how he can play videogames while driving on a closed course in Portland ...</p>\n\n<a href=\"https://www.wsj.com/articles/teslas-touch-screen-gaming-probed-by-u-s-auto-safety-regulator-11640187212?mod=hp_lista_pos5\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.wsj.com/articles/teslas-touch-screen-gaming-probed-by-u-s-auto-safety-regulator-11640187212?mod=hp_lista_pos5","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158266085","content_text":"The National Highway Traffic Safety Administration says the screen may distract drivers\nVince Patton, a new Tesla owner, shows how he can play videogames while driving on a closed course in Portland earlier this month.\nThe top U.S. auto-safety regulator has opened an investigation into a Tesla Inc. feature that allows people—including the driver—to play games on a touch screen while the vehicle is in motion.\nThe ability to play games while driving has been available for roughly a year in some vehicles and “may distract the driver and increase the risk of a crash,” the National Highway Traffic Safety Administration said in a document made public Wednesday. The feature previously was only enabled while vehicles were in park, the agency said, adding it launched the probe to evaluate the potential for driver distraction.\nThe probe covers about 580,000 Tesla vehicles of all types and model years 2017 to present in some cases, NHTSA said.\nTesla didn’t immediately respond to a request for comment.\nWhen a vehicle is in drive, Tesla asks those seeking to play games on the centrally located front touch screen to confirm they are a passenger. Available games include solitaire, Sky Force Reloaded and The Battle of Polytopia. Certain other games aren’t available unless the vehicle is parked.\nNHTSA said it wasn’t aware of any crashes or injuries linked to the feature. The agency received a complaint about the functionality earlier this year that urged the regulator to prohibit live video and interactive web browsing on the centrally located front touch screen while Teslas are in motion.\nTesla Chief Executive Elon Musk has said he thinks entertainment will be highly desired once vehicles become autonomous. Tesla’s advanced driver-assistance system, known as Autopilot, doesn’t make vehicles autonomous.\n\nNHTSA investigations can lead to recalls. Tesla recalled roughly 135,000 vehicles earlier this year over touch-screen failures after NHTSA urged it to do so.\nThe agency is also investigating Tesla’s Autopilot system after a series of crashes involving Teslas and one or more parked emergency vehicles.","news_type":1},"isVote":1,"tweetType":1,"viewCount":732,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691255694,"gmtCreate":1640215033809,"gmtModify":1640215033809,"author":{"id":"3584951930259825","authorId":"3584951930259825","name":"Henrywong","avatar":"https://static.tigerbbs.com/56257d5353428bab1d80ae29b9da9fb3","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691255694","repostId":"1131862374","repostType":4,"repost":{"id":"1131862374","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640213195,"share":"https://www.laohu8.com/m/news/1131862374?lang=&edition=full","pubTime":"2021-12-23 06:46","market":"us","language":"en","title":"U.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use","url":"https://stock-news.laohu8.com/highlight/detail?id=1131862374","media":"Reuters","summary":"Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's antiviral COVID-19 pill fo","content":"<p>Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading Omicron variant.</p>\n<p>Pfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.</p>\n<p>Pfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.</p>\n<p>\"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,\" said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.</p>\n<p>\"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,\" Adalja added.</p>\n<p>Pfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.</p>\n<p>The Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing plans for more federal vaccination and testing sites.</p>\n<p>The pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.</p>\n<p>Monoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.</p>\n<p>The Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.</p>\n<p>The FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.</p>\n<p>The drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.</p>\n<p>While the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).</p>\n<p>The second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.</p>\n<p>Pfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.</p>\n<p>Pfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.</p>\n<p>A rival pill from Merck & Co is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-23 06:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading Omicron variant.</p>\n<p>Pfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.</p>\n<p>Pfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.</p>\n<p>\"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,\" said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.</p>\n<p>\"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,\" Adalja added.</p>\n<p>Pfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.</p>\n<p>The Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing plans for more federal vaccination and testing sites.</p>\n<p>The pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.</p>\n<p>Monoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.</p>\n<p>The Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.</p>\n<p>The FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.</p>\n<p>The drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.</p>\n<p>While the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).</p>\n<p>The second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.</p>\n<p>Pfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.</p>\n<p>Pfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.</p>\n<p>A rival pill from Merck & Co is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131862374","content_text":"Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading Omicron variant.\nPfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.\nPfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.\n\"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,\" said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.\n\"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,\" Adalja added.\nPfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.\nThe Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing plans for more federal vaccination and testing sites.\nThe pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.\nMonoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.\nThe Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.\nThe FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.\nThe drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.\nWhile the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).\nThe second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.\nPfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.\nPfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.\nA rival pill from Merck & Co is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.","news_type":1},"isVote":1,"tweetType":1,"viewCount":785,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":697900865,"gmtCreate":1642183149112,"gmtModify":1642183149204,"author":{"id":"3584951930259825","authorId":"3584951930259825","name":"Henrywong","avatar":"https://static.tigerbbs.com/56257d5353428bab1d80ae29b9da9fb3","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"People are dreaming and think that electric car are flying out of the showrooms. Elon Musk certainly has successfully build your dream more than BYD","listText":"People are dreaming and think that electric car are flying out of the showrooms. Elon Musk certainly has successfully build your dream more than BYD","text":"People are dreaming and think that electric car are flying out of the showrooms. Elon Musk certainly has successfully build your dream more than BYD","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/697900865","repostId":"2203126977","repostType":4,"repost":{"id":"2203126977","pubTimestamp":1642174200,"share":"https://www.laohu8.com/m/news/2203126977?lang=&edition=full","pubTime":"2022-01-14 23:30","market":"us","language":"en","title":"Are Electric Vehicle Stocks Overhyped?","url":"https://stock-news.laohu8.com/highlight/detail?id=2203126977","media":"Motley Fool","summary":"The short answer: Almost definitely.","content":"<html><head></head><body><p>The excitement around electric vehicle stocks is palpable. From <b>Rivian</b> (NASDAQ:RIVN) at a $76 billion market cap with no revenue to <b>Tesla</b> (NASDAQ:TSLA) breaching a $1.1 trillion market cap when it was valued under $100 billion less than three years ago, many investors are bullish on the opportunity in electric vehicles.</p><p>And why wouldn't they be? The industry is growing quickly, up 26% year over year from 2020, and is going after a gigantic market opportunity in the worldwide car market. But just because these stocks are in a large, growing industry doesn't mean they will be great investments over the next decade. Just ask <b>Cisco Systems</b> investors who bought stock in 1999 and 2000.</p><p>Are electric vehicle stocks overhyped? Yes. Let me explain why.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/90344f91dac6378d78934846de60ce59\" tg-width=\"700\" tg-height=\"465\" referrerpolicy=\"no-referrer\"/><span>Image source: Getty Images.</span></p><h2>Growth is strong, and the market opportunity is massive</h2><p>To start out, let's give some context around the global opportunity in electric vehicles and the overall automotive industry. In 2021, it is estimated that 6.4 million electric vehicles (EVs) were sold around the world, of which 4 million of these were all-electric and 2.4 million plug-in hybrids. That total number is up 26% from 2020.</p><p>In 2022, analysts are actually expecting this growth to accelerate due to the number of models being available in the U.S. jumping from 62 to 100. If that is the case, global annual sales for electric vehicles should hit 10 million in the near future. For reference, 66 million total cars are estimated to have been sold around the world in 2021.</p><p>Those are all high-level numbers, but what about the financial opportunity? Assuming an average selling price of $25,000, 10 million EV sales would equate to $250 billion in annual sales. At 50 million EVs, which assumes they take over the majority of the auto market, that equates to $1.25 trillion in sales. Clearly, the opportunity is massive from a revenue standpoint.</p><h2>Margins will be low</h2><p>While the revenue opportunity for EVs is large, these manufacturing businesses also have low margins. For example, let's look at <b>Toyota </b>(NYSE:TM), the largest automaker in the world, with an estimated 8.5% market share in 2019. Over the last 12 months, the company has brought in $281 billion in revenue. On that revenue, only $31 billion turned into operating income, or an 11% operating margin.</p><p>Tesla, the biggest pure-play EV maker, is seeing just shy of 10% operating margins on $47 billion in revenue. Given the reduction in manufacturing complications of a battery pack versus an internal combustion engine, EV makers may achieve better operating margins than 11% at scale. But they still require bending metal to succeed, so the likelihood they will be much higher than 11% on average over the long term seems unlikely.</p><p>What's more, automotive businesses require tons of capital expenditures relative to their sales just to stay afloat. For example, Toyota spent almost $35 billion on capital investments over the last 12 months. Given its profit margins, that makes it very difficult for the company to return excess cash to shareholders -- which is the <i>only</i> driver of shareholder value in the long run. This is why Toyota's stock historically trades at a price-to-earnings (P/E) ratio at or around 10. And EV stocks will have a similar fate due to this capital intensity.</p><h2>Expectations are too high</h2><p>Let's move back to our revenue example. If annual EV sales reach $1.25 trillion and we assign a generous 15% operating margin across the industry, there will be $180 billion in annual operating income once EV sales hit 50 million a year. Remember, sales are currently at only 6.4 million, including plug-in hybrids, so this is a long way off. On that $180 billion in operating income, if you give it a 21% corporate tax rate, that is $142.2 billion in annual net income across the industry.</p><p>Put an average P/E of 10 (remember, this is typical for automotive companies because of the capital intensity) on the stocks, and you have $1.42 trillion in combined market value once EVs reach maturity. Looking at the five pure-play EV stocks right now, which are Tesla, Rivian, <b>Lucid Motors </b>(NASDAQ:LCID), <b>Nio </b>(NYSE:NIO), and <b>Xpeng </b>(NYSE:XPEV), their combined market caps are <i>currently</i> $1.34 trillion, or pretty darn close to what the whole industry will be worth at maturity with optimistic margin and growth assumptions.</p><p>And this doesn't include the legacy automakers like Toyota, <b>Ford Motor Company</b>, <b>GM</b>, and <b>Volkswagen</b>, which are all making major investments into EVs. Assuming none of these legacy manufacturers will at least capture some of the $1.42 trillion market value is naive, in my opinion.</p><p>Given all these numbers, it is clear that the electric vehicle market is overhyped. If you are invested in <a href=\"https://laohu8.com/S/AONE.U\">one</a> of these companies, or even a legacy automaker, you need to be confident in that specific company's ability to win market share and beat all these competitors. If that doesn't happen, it is likely your investment will go very poorly over the next decade.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Electric Vehicle Stocks Overhyped?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Electric Vehicle Stocks Overhyped?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-14 23:30 GMT+8 <a href=https://www.fool.com/investing/2022/01/14/are-electric-vehicle-stocks-overhyped-tesla/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The excitement around electric vehicle stocks is palpable. From Rivian (NASDAQ:RIVN) at a $76 billion market cap with no revenue to Tesla (NASDAQ:TSLA) breaching a $1.1 trillion market cap when it was...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/14/are-electric-vehicle-stocks-overhyped-tesla/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","RIVN":"Rivian Automotive, Inc.","NIO":"蔚来","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","BK4509":"腾讯概念","BK4525":"远程办公概念","BK4527":"明星科技股","BK4020":"通信设备","BK4550":"红杉资本持仓","BK4526":"热门中概股","LCID":"Lucid Group Inc","BK4551":"寇图资本持仓","BK4505":"高瓴资本持仓","BK4560":"网络安全概念","BK4504":"桥水持仓","BK4099":"汽车制造商","BK4548":"巴美列捷福持仓","CSCO":"思科","TSLA":"特斯拉","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","XPEV":"小鹏汽车","BK4531":"中概回港概念","TM":"丰田汽车"},"source_url":"https://www.fool.com/investing/2022/01/14/are-electric-vehicle-stocks-overhyped-tesla/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2203126977","content_text":"The excitement around electric vehicle stocks is palpable. From Rivian (NASDAQ:RIVN) at a $76 billion market cap with no revenue to Tesla (NASDAQ:TSLA) breaching a $1.1 trillion market cap when it was valued under $100 billion less than three years ago, many investors are bullish on the opportunity in electric vehicles.And why wouldn't they be? The industry is growing quickly, up 26% year over year from 2020, and is going after a gigantic market opportunity in the worldwide car market. But just because these stocks are in a large, growing industry doesn't mean they will be great investments over the next decade. Just ask Cisco Systems investors who bought stock in 1999 and 2000.Are electric vehicle stocks overhyped? Yes. Let me explain why.Image source: Getty Images.Growth is strong, and the market opportunity is massiveTo start out, let's give some context around the global opportunity in electric vehicles and the overall automotive industry. In 2021, it is estimated that 6.4 million electric vehicles (EVs) were sold around the world, of which 4 million of these were all-electric and 2.4 million plug-in hybrids. That total number is up 26% from 2020.In 2022, analysts are actually expecting this growth to accelerate due to the number of models being available in the U.S. jumping from 62 to 100. If that is the case, global annual sales for electric vehicles should hit 10 million in the near future. For reference, 66 million total cars are estimated to have been sold around the world in 2021.Those are all high-level numbers, but what about the financial opportunity? Assuming an average selling price of $25,000, 10 million EV sales would equate to $250 billion in annual sales. At 50 million EVs, which assumes they take over the majority of the auto market, that equates to $1.25 trillion in sales. Clearly, the opportunity is massive from a revenue standpoint.Margins will be lowWhile the revenue opportunity for EVs is large, these manufacturing businesses also have low margins. For example, let's look at Toyota (NYSE:TM), the largest automaker in the world, with an estimated 8.5% market share in 2019. Over the last 12 months, the company has brought in $281 billion in revenue. On that revenue, only $31 billion turned into operating income, or an 11% operating margin.Tesla, the biggest pure-play EV maker, is seeing just shy of 10% operating margins on $47 billion in revenue. Given the reduction in manufacturing complications of a battery pack versus an internal combustion engine, EV makers may achieve better operating margins than 11% at scale. But they still require bending metal to succeed, so the likelihood they will be much higher than 11% on average over the long term seems unlikely.What's more, automotive businesses require tons of capital expenditures relative to their sales just to stay afloat. For example, Toyota spent almost $35 billion on capital investments over the last 12 months. Given its profit margins, that makes it very difficult for the company to return excess cash to shareholders -- which is the only driver of shareholder value in the long run. This is why Toyota's stock historically trades at a price-to-earnings (P/E) ratio at or around 10. And EV stocks will have a similar fate due to this capital intensity.Expectations are too highLet's move back to our revenue example. If annual EV sales reach $1.25 trillion and we assign a generous 15% operating margin across the industry, there will be $180 billion in annual operating income once EV sales hit 50 million a year. Remember, sales are currently at only 6.4 million, including plug-in hybrids, so this is a long way off. On that $180 billion in operating income, if you give it a 21% corporate tax rate, that is $142.2 billion in annual net income across the industry.Put an average P/E of 10 (remember, this is typical for automotive companies because of the capital intensity) on the stocks, and you have $1.42 trillion in combined market value once EVs reach maturity. Looking at the five pure-play EV stocks right now, which are Tesla, Rivian, Lucid Motors (NASDAQ:LCID), Nio (NYSE:NIO), and Xpeng (NYSE:XPEV), their combined market caps are currently $1.34 trillion, or pretty darn close to what the whole industry will be worth at maturity with optimistic margin and growth assumptions.And this doesn't include the legacy automakers like Toyota, Ford Motor Company, GM, and Volkswagen, which are all making major investments into EVs. Assuming none of these legacy manufacturers will at least capture some of the $1.42 trillion market value is naive, in my opinion.Given all these numbers, it is clear that the electric vehicle market is overhyped. If you are invested in one of these companies, or even a legacy automaker, you need to be confident in that specific company's ability to win market share and beat all these competitors. If that doesn't happen, it is likely your investment will go very poorly over the next decade.","news_type":1},"isVote":1,"tweetType":1,"viewCount":629,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691254646,"gmtCreate":1640215147121,"gmtModify":1640215147121,"author":{"id":"3584951930259825","authorId":"3584951930259825","name":"Henrywong","avatar":"https://static.tigerbbs.com/56257d5353428bab1d80ae29b9da9fb3","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691254646","repostId":"1158266085","repostType":4,"isVote":1,"tweetType":1,"viewCount":732,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694447679,"gmtCreate":1642090581000,"gmtModify":1642090581000,"author":{"id":"3584951930259825","authorId":"3584951930259825","name":"Henrywong","avatar":"https://static.tigerbbs.com/56257d5353428bab1d80ae29b9da9fb3","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Start flying high","listText":"Start flying high","text":"Start flying high","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/694447679","repostId":"1105224732","repostType":4,"repost":{"id":"1105224732","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1642086896,"share":"https://www.laohu8.com/m/news/1105224732?lang=&edition=full","pubTime":"2022-01-13 23:14","market":"us","language":"en","title":"Airline stocks jumped in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1105224732","media":"Tiger Newspress","summary":"Airline stocks jumped in morning trading. Delta Air Lines,Southwest Airlines,United Continental and ","content":"<html><head></head><body><p>Airline stocks jumped in morning trading. <a href=\"https://laohu8.com/S/DAL\">Delta Air Lines</a>,<a href=\"https://laohu8.com/S/LUV\">Southwest Airlines</a>,<a href=\"https://laohu8.com/S/UAL\">United Continental</a> and <a href=\"https://laohu8.com/S/AAL\">American Airlines</a> rose between 2% and 5%.</p><p><img src=\"https://static.tigerbbs.com/5337c1fa70a52ef20ee586624787937c\" tg-width=\"1080\" tg-height=\"1915\" referrerpolicy=\"no-referrer\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Airline stocks jumped in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAirline stocks jumped in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-13 23:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Airline stocks jumped in morning trading. <a href=\"https://laohu8.com/S/DAL\">Delta Air Lines</a>,<a href=\"https://laohu8.com/S/LUV\">Southwest Airlines</a>,<a href=\"https://laohu8.com/S/UAL\">United Continental</a> and <a href=\"https://laohu8.com/S/AAL\">American Airlines</a> rose between 2% and 5%.</p><p><img src=\"https://static.tigerbbs.com/5337c1fa70a52ef20ee586624787937c\" tg-width=\"1080\" tg-height=\"1915\" referrerpolicy=\"no-referrer\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LUV":"西南航空","UAL":"联合大陆航空","AAL":"美国航空","DAL":"达美航空","BK4500":"航空公司","BK4547":"WSB热门概念","BK4008":"航空公司"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105224732","content_text":"Airline stocks jumped in morning trading. Delta Air Lines,Southwest Airlines,United Continental and American Airlines rose between 2% and 5%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1075,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691254441,"gmtCreate":1640215198079,"gmtModify":1640215198079,"author":{"id":"3584951930259825","authorId":"3584951930259825","name":"Henrywong","avatar":"https://static.tigerbbs.com/56257d5353428bab1d80ae29b9da9fb3","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691254441","repostId":"2193192429","repostType":4,"isVote":1,"tweetType":1,"viewCount":741,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":630877408,"gmtCreate":1642789463215,"gmtModify":1642789463328,"author":{"id":"3584951930259825","authorId":"3584951930259825","name":"Henrywong","avatar":"https://static.tigerbbs.com/56257d5353428bab1d80ae29b9da9fb3","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"It is completely wrong logic for stock options to drive stock price. Over trading in stock options has now become a problem ","listText":"It is completely wrong logic for stock options to drive stock price. Over trading in stock options has now become a problem ","text":"It is completely wrong logic for stock options to drive stock price. Over trading in stock options has now become a problem","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/630877408","repostId":"1165558393","repostType":4,"isVote":1,"tweetType":1,"viewCount":564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691257512,"gmtCreate":1640215263910,"gmtModify":1640215263910,"author":{"id":"3584951930259825","authorId":"3584951930259825","name":"Henrywong","avatar":"https://static.tigerbbs.com/56257d5353428bab1d80ae29b9da9fb3","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691257512","repostId":"2193192720","repostType":4,"repost":{"id":"2193192720","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640185119,"share":"https://www.laohu8.com/m/news/2193192720?lang=&edition=full","pubTime":"2021-12-22 22:58","market":"us","language":"en","title":"Tesla, authorities submit documents for German plant approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2193192720","media":"Reuters","summary":"BERLIN, Dec 22 - Tesla and relevant authorities have submitted all the documents necessary for the approval process for its planned factory near Berlin, the environment ministry of the German state of Brandenburg said on Wednesday.The approval process is still ongoing, the ministry said.Tesla could not be immediately reached for comment.Due to environmental resistance and red tape, it remained unclear when the first vehicles will roll off the production line at the site. Brandenburg premier Die","content":"<p>BERLIN, Dec 22 (Reuters) - Tesla and relevant authorities have submitted all the documents necessary for the approval process for its planned factory near Berlin, the environment ministry of the German state of Brandenburg said on Wednesday.</p>\n<p>The approval process is still ongoing, the ministry said.</p>\n<p>Tesla could not be immediately reached for comment.</p>\n<p>Due to environmental resistance and red tape, it remained unclear when the first vehicles will roll off the production line at the site. Brandenburg premier Dietmar Woidke had recently suggested a decision might come in early 2022.</p>\n<p>Tesla has repeatedly had to push back the expected opening of the factory and Chief Executive Elon Musk has regularly travelled to Germany to check on the plant's progress, criticising German bureaucracy for slowing down construction.</p>\n<p>Since Tesla expanded its original proposal to include a battery factory, the construction plans had to undergo a renewed process of public consultation which ended on Nov. 22.</p>\n<p>The response to all objections raised in that consultation is a prerequisite for a final building permit.</p>\n<p>Currently, Tesla is only working on the factory on the basis of preliminary building permits.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla, authorities submit documents for German plant approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla, authorities submit documents for German plant approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-22 22:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BERLIN, Dec 22 (Reuters) - Tesla and relevant authorities have submitted all the documents necessary for the approval process for its planned factory near Berlin, the environment ministry of the German state of Brandenburg said on Wednesday.</p>\n<p>The approval process is still ongoing, the ministry said.</p>\n<p>Tesla could not be immediately reached for comment.</p>\n<p>Due to environmental resistance and red tape, it remained unclear when the first vehicles will roll off the production line at the site. Brandenburg premier Dietmar Woidke had recently suggested a decision might come in early 2022.</p>\n<p>Tesla has repeatedly had to push back the expected opening of the factory and Chief Executive Elon Musk has regularly travelled to Germany to check on the plant's progress, criticising German bureaucracy for slowing down construction.</p>\n<p>Since Tesla expanded its original proposal to include a battery factory, the construction plans had to undergo a renewed process of public consultation which ended on Nov. 22.</p>\n<p>The response to all objections raised in that consultation is a prerequisite for a final building permit.</p>\n<p>Currently, Tesla is only working on the factory on the basis of preliminary building permits.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","BK4527":"明星科技股","TSLA":"特斯拉","BK4534":"瑞士信贷持仓","BK4555":"新能源车","BK4099":"汽车制造商","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4548":"巴美列捷福持仓","BK4550":"红杉资本持仓"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193192720","content_text":"BERLIN, Dec 22 (Reuters) - Tesla and relevant authorities have submitted all the documents necessary for the approval process for its planned factory near Berlin, the environment ministry of the German state of Brandenburg said on Wednesday.\nThe approval process is still ongoing, the ministry said.\nTesla could not be immediately reached for comment.\nDue to environmental resistance and red tape, it remained unclear when the first vehicles will roll off the production line at the site. Brandenburg premier Dietmar Woidke had recently suggested a decision might come in early 2022.\nTesla has repeatedly had to push back the expected opening of the factory and Chief Executive Elon Musk has regularly travelled to Germany to check on the plant's progress, criticising German bureaucracy for slowing down construction.\nSince Tesla expanded its original proposal to include a battery factory, the construction plans had to undergo a renewed process of public consultation which ended on Nov. 22.\nThe response to all objections raised in that consultation is a prerequisite for a final building permit.\nCurrently, Tesla is only working on the factory on the basis of preliminary building permits.","news_type":1},"isVote":1,"tweetType":1,"viewCount":887,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691255694,"gmtCreate":1640215033809,"gmtModify":1640215033809,"author":{"id":"3584951930259825","authorId":"3584951930259825","name":"Henrywong","avatar":"https://static.tigerbbs.com/56257d5353428bab1d80ae29b9da9fb3","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691255694","repostId":"1131862374","repostType":4,"repost":{"id":"1131862374","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640213195,"share":"https://www.laohu8.com/m/news/1131862374?lang=&edition=full","pubTime":"2021-12-23 06:46","market":"us","language":"en","title":"U.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use","url":"https://stock-news.laohu8.com/highlight/detail?id=1131862374","media":"Reuters","summary":"Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's antiviral COVID-19 pill fo","content":"<p>Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading Omicron variant.</p>\n<p>Pfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.</p>\n<p>Pfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.</p>\n<p>\"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,\" said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.</p>\n<p>\"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,\" Adalja added.</p>\n<p>Pfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.</p>\n<p>The Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing plans for more federal vaccination and testing sites.</p>\n<p>The pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.</p>\n<p>Monoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.</p>\n<p>The Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.</p>\n<p>The FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.</p>\n<p>The drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.</p>\n<p>While the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).</p>\n<p>The second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.</p>\n<p>Pfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.</p>\n<p>Pfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.</p>\n<p>A rival pill from Merck & Co is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-23 06:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading Omicron variant.</p>\n<p>Pfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.</p>\n<p>Pfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.</p>\n<p>\"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,\" said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.</p>\n<p>\"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,\" Adalja added.</p>\n<p>Pfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.</p>\n<p>The Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing plans for more federal vaccination and testing sites.</p>\n<p>The pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.</p>\n<p>Monoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.</p>\n<p>The Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.</p>\n<p>The FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.</p>\n<p>The drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.</p>\n<p>While the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).</p>\n<p>The second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.</p>\n<p>Pfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.</p>\n<p>Pfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.</p>\n<p>A rival pill from Merck & Co is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131862374","content_text":"Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading Omicron variant.\nPfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.\nPfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.\n\"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,\" said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.\n\"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,\" Adalja added.\nPfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.\nThe Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing plans for more federal vaccination and testing sites.\nThe pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.\nMonoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.\nThe Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.\nThe FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.\nThe drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.\nWhile the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).\nThe second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.\nPfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.\nPfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.\nA rival pill from Merck & Co is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.","news_type":1},"isVote":1,"tweetType":1,"viewCount":785,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}